FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

FibroBiologics announced completion of cGMP manufacturing for CYWC628 drug product and site onboarding for a phase 1/2 clinical trial in diabetic foot ulcers, with first patient dosing expected in Q2 2026. The company reported positive preclinical results for burn and degenerative disc disease programs, raised $3M in capital, and regained full Nasdaq compliance. Q1 2026 showed R&D expenses of $3.0M and a net loss of $5.0M, with cash reserves of $1.5M at quarter-end.

04/30/2026, 5:55 PM • GlobeNewswire

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight

Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.

04/14/2026, 1:00 PM • GlobeNewswire

FibroBiologics Announces Pricing of $3 Million Public Offering

FibroBiologics priced a public offering of 2.27 million shares and warrants at $1.32 per share, expecting to raise approximately $3 million in gross proceeds before fees. The company also announced successful manufacturing of CYWC628 drug product to support an upcoming diabetic foot ulcer clinical trial. Additionally, the company completed a reverse stock split to regain Nasdaq compliance with bid price requirements.

03/31/2026, 8:00 PM • GlobeNewswire

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

The global cell therapy market is projected to surpass $8.2 billion in 2026, with CAR T-cell therapy expanding at 18% annually. Several companies are advancing manufacturing milestones and clinical breakthroughs: Avaí Bio initiated Master Cell Bank production for α-Klotho anti-aging therapy; FibroBiologics secured a patent for fibroblast cell therapy for osteoporosis; Fate Therapeutics achieved same-day hospital discharge for off-the-shelf CAR T-cell patients; Mesoblast presented favorable survival data for Ryoncil® in graft-versus-host disease; and Longeveron published Phase 2b results showing stem cell therapy improved physical condition in age-related frailty patients.

03/03/2026, 10:02 AM • Benzinga

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics, a clinical-stage biotechnology company, closed a $4 million registered direct offering by issuing common stock and pre-funded warrants to an existing shareholder, with proceeds intended for general corporate purposes and debt satisfaction.

11/19/2025, 7:03 PM • Benzinga

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics completed a $4 million registered direct offering by selling common stock and pre-funded warrants to an existing shareholder, with the purchase price paid in gold coins. The company intends to use proceeds for general corporate purposes and debt satisfaction.

11/19/2025, 7:03 PM • GlobeNewswire